Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.
Passage Bio, a US-based company developing treatments for neurological diseases based on research at University of Pennsylvania, has received $115.5m in a series A round that included Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly. The round was led by OrbiMed and included fellow healthcare investment firm Vivo Capital as well as…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
